I was just looking at the results of Ilfeld's opioid study, and it not only failed for the opioid consumption part.... it failed for the pain VAS part too. In most VAS categories the active group was roughly equal to the placebo group. In some VAS categories the active group actually had MORE pain than the placebo group.
It's very unlikely that Ilfeld will publish this study. BIEL doesn't WANT him to publish this study. So, I wonder how CEO Whelan is progressing with her quest to get RecoveryRx included in the NOPAIN Act without this study? She has missed the 2025 deadline but maybe she has a plan for 2026? the NOPAIN Act runs through 2027 so there's still hope for 2026 and 2027.
Whelan wants you all to call her and ask!
Meanwhile.... Ilfeld's SofPulse study hasn't finished yet. It will be interesting to see whether the SofPulse device fares better than RecoveryRx. Primary Completion was supposed to finish in June and Study Completion expected in December.